Skip to main content
. Author manuscript; available in PMC: 2018 Mar 15.
Published in final edited form as: Cancer Res. 2017 Jan 20;77(6):1465–1475. doi: 10.1158/0008-5472.CAN-16-1646

Figure 5. Intratumoral and intraorgan distribution of Doxil® in B16F10 tumors.

Figure 5

Tumor bearing mice were treated with either Doxil or a combination of Doxil and tPA. Animals were sacrificed 24 h later, tumors were collected and fluorescence of doxorubicin was imaged using confocal microscopy. Shown here are representative micrographs of tumors treated with (A) Doxil® or (B) combination of Doxil® and tPA. Arrows indicate fluorescence in tumor sections. Relative fluorescence intensity normalized to area in the entire tissue section and the central 40% and 10% of the tissue area in (C) tumor (D) liver (E) lung (F) spleen (G) brain. Data is represented as mean ± S.E.M., n=3 animals/group. Three tumor sections and one section of normal tissue from each animal were analyzed.